Current and Future Treatment Strategies for Rhabdomyosarcoma

Overview

Journal Front Oncol

Specialty Oncology

Date 2020 Jan 11

PMID 31921698

Citations 70

Authors

Celine Chen

Heathcliff Dorado Garcia

Monika Scheer

Anton G Henssen

Affiliations

Soon will be listed here.

Abstract

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children, and can be subcategorized histologically and/or based on PAX-FOXO1 fusion gene status. Over the last four decades, there have been no significant improvements in clinical outcomes for advanced and metastatic RMS patients, underscoring a need for new treatment options for these groups. Despite significant advancements in our understanding of the genomic landscape and underlying biological mechanisms governing RMS that have informed the identification of novel therapeutic targets, development of these therapies in clinical trials has lagged far behind. In this review, we summarize the current frontline multi-modality therapy for RMS according to pediatric protocols, highlight emerging targeted therapies and immunotherapies identified by preclinical studies, and discuss early clinical trial data and the implications they hold for future clinical development.

Citing Articles

Rhabdomyosarcoma with pancreatic metastases: A case report.

Luo S, Li J, Zeng J, Li Y, Wang J Heliyon. 2025; 11(4):e42634.

PMID: 40034278 PMC: 11874728. DOI: 10.1016/j.heliyon.2025.e42634.

Prognostic factors in patients with localized and metastatic alveolar rhabdomyosarcoma. A report from two studies and two registries of the Cooperative Weichteilsarkom Studiengruppe CWS.

Koscielniak E, Stegmaier S, Ljungman G, Kazanowska B, Niggli F, Ladenstein R Cancer Med. 2025; 14(1):e70215.

PMID: 39781573 PMC: 11712121. DOI: 10.1002/cam4.70215.

Enhancement of anti-sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2-targeted CAR.

Lam P, Omer N, Wong J, Tu C, Alim L, Rossi G Clin Transl Med. 2025; 15(1):e70140.

PMID: 39763064 PMC: 11705447. DOI: 10.1002/ctm2.70140.

Synthetic inhibition of SREBP2 and the mevalonate pathway blocks rhabdomyosarcoma tumor growth in vitro and in vivo and promotes chemosensitization.

Codenotti S, Asperti M, Poli M, Lorenzi L, Pietrantoni A, Cassandri M Mol Metab. 2024; 92:102085.

PMID: 39706565 PMC: 11750561. DOI: 10.1016/j.molmet.2024.102085.

Primary Esophageal Rhabdomyosarcoma: An Exceptionally Rare Cause of Pediatric Dysphagia.

Ataollahi M, Mashhadiagha A, Karbasian F, Moshfeghinia R, Arabpour J, Geramizadeh B Case Rep Gastrointest Med. 2024; 2024:3648155.

PMID: 39703342 PMC: 11658847. DOI: 10.1155/crgm/3648155.

References

Crist W, Gehan E, Ragab A, Dickman P, Donaldson S, Fryer C . The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol. 1995; 13(3):610-30. DOI: 10.1200/JCO.1995.13.3.610. View

Dietz K, Miller P, Iyengar A, Loupe J, Hollenbach A . Identification of serines 201 and 209 as sites of Pax3 phosphorylation and the altered phosphorylation status of Pax3-FOXO1 during early myogenic differentiation. Int J Biochem Cell Biol. 2011; 43(6):936-45. PMC: 3095663. DOI: 10.1016/j.biocel.2011.03.010. View

Harris M, Gieser P, Goorin A, Ayala A, Shochat S, Ferguson W . Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study. J Clin Oncol. 1998; 16(11):3641-8. DOI: 10.1200/JCO.1998.16.11.3641. View

Mackall C, Rhee E, Read E, Khuu H, Leitman S, Bernstein D . A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin Cancer Res. 2008; 14(15):4850-8. PMC: 2497450. DOI: 10.1158/1078-0432.CCR-07-4065. View

Satheesha S, Manzella G, Bovay A, Casanova E, Bode P, Belle R . Targeting hedgehog signaling reduces self-renewal in embryonal rhabdomyosarcoma. Oncogene. 2015; 35(16):2020-30. PMC: 5399168. DOI: 10.1038/onc.2015.267. View

Briscoe J, Therond P . The mechanisms of Hedgehog signalling and its roles in development and disease. Nat Rev Mol Cell Biol. 2013; 14(7):416-29. DOI: 10.1038/nrm3598. View

Ladra M, Edgington S, Mahajan A, Grosshans D, Szymonifka J, Khan F . A dosimetric comparison of proton and intensity modulated radiation therapy in pediatric rhabdomyosarcoma patients enrolled on a prospective phase II proton study. Radiother Oncol. 2014; 113(1):77-83. PMC: 4298831. DOI: 10.1016/j.radonc.2014.08.033. View

Meyer W . Maintenance chemotherapy in rhabdomyosarcoma: the new standard of care. Lancet Oncol. 2019; 20(11):1476-1477. DOI: 10.1016/S1470-2045(19)30618-7. View

Chonghaile T, Sarosiek K, Vo T, Ryan J, Tammareddi A, Gaizo Moore V . Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science. 2011; 334(6059):1129-33. PMC: 3280949. DOI: 10.1126/science.1206727. View

10.

Yohe M, Heske C, Stewart E, Adamson P, Ahmed N, Antonescu C . Insights into pediatric rhabdomyosarcoma research: Challenges and goals. Pediatr Blood Cancer. 2019; 66(10):e27869. PMC: 6707829. DOI: 10.1002/pbc.27869. View

11.

Lord C, Ashworth A . PARP inhibitors: Synthetic lethality in the clinic. Science. 2017; 355(6330):1152-1158. PMC: 6175050. DOI: 10.1126/science.aam7344. View

12.

Yohe M, Gryder B, Shern J, Song Y, Chou H, Sindiri S . MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma. Sci Transl Med. 2018; 10(448). PMC: 8054766. DOI: 10.1126/scitranslmed.aan4470. View

13.

Chicas-Sett R, Morales-Orue I, Rodriguez-Abreu D, Lara-Jimenez P . Combining radiotherapy and ipilimumab induces clinically relevant radiation-induced abscopal effects in metastatic melanoma patients: A systematic review. Clin Transl Radiat Oncol. 2018; 9:5-11. PMC: 5862682. DOI: 10.1016/j.ctro.2017.12.004. View

14.

Weigel B, Breitfeld P, Hawkins D, Crist W, Baker K . Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma. J Pediatr Hematol Oncol. 2001; 23(5):272-6. DOI: 10.1097/00043426-200106000-00007. View

15.

Dantonello T, Int-Veen C, Schuck A, Seitz G, Leuschner I, Nathrath M . Survival following disease recurrence of primary localized alveolar rhabdomyosarcoma. Pediatr Blood Cancer. 2013; 60(8):1267-73. DOI: 10.1002/pbc.24488. View

16.

Gallego S, Zanetti I, Orbach D, Ranchere D, Shipley J, Zin A . Fusion status in patients with lymph node-positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: Experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). Cancer. 2018; 124(15):3201-3209. DOI: 10.1002/cncr.31553. View

17.

Kahen E, Yu D, Harrison D, Clark J, Hingorani P, Cubitt C . Identification of clinically achievable combination therapies in childhood rhabdomyosarcoma. Cancer Chemother Pharmacol. 2016; 78(2):313-23. PMC: 4965487. DOI: 10.1007/s00280-016-3077-8. View

18.

Chmielecki J, Foo J, Oxnard G, Hutchinson K, Ohashi K, Somwar R . Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med. 2011; 3(90):90ra59. PMC: 3500629. DOI: 10.1126/scitranslmed.3002356. View

19.

Konermann S, Brigham M, Trevino A, Joung J, Abudayyeh O, Barcena C . Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature. 2014; 517(7536):583-8. PMC: 4420636. DOI: 10.1038/nature14136. View

20.

Sandler E, Lyden E, Ruymann F, Maurer H, Wharam M, Parham D . Efficacy of ifosfamide and doxorubicin given as a phase II "window" in children with newly diagnosed metastatic rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group. Med Pediatr Oncol. 2001; 37(5):442-8. DOI: 10.1002/mpo.1227. View